It is estimated, that globally more than 300 million people suffer from depression. Latest research has shown that the pandemic might has added another 50 million on top of that. Sadly, 1 in 3 patients do not benefit from current available treatments and develop treatment resistant depression over time.
Unfortunately, there are not a lot of options left for those patients. While there have been more than 80 drugs approved in oncology since 2015 it was only 7 in mental health.
The Kieger Impact Healthcare Fund has a strong focus on mental health and also investing in new and more holistic psychedelic therapies.
The field of psychedelic drugs has been re-emerging quite a lot over the last years with very good and promising clinical data and also FDA breakthrough designations for example for a psylocibin therapy. Psylocibin is the active psychedelic substance in more than 200 fungi worldwide.
Hopefully, these new and more holistic therapies will soon help millions of people around the globe to get back to their families and friends, to get back to work and also to get back to joy in their lifes.
Link to our funds: https://kieger.com/ucits/
Rarely are health inequalities more apparent than when walking around San Francisco during the J.P. Morgan Healthcare Conference. In our chart of the month, Raphael Oesch (Portfolio Manager), takes a look at the statistics and discusses some of the reasons behind the figures.
We recently attended the 41st J.P. Morgan Healthcare Conference in San Francisco, which took place from January 9th to January 12th 2023. Our overall conclusion from the conference is that the industry remains in good shape. The key themes that emerged during the week from a devices and services perspective were, the rise of value-based care and innovation & digitalisation. However, it also became clear that the macroeconomic environment is still the dominant force behind (sub) sector performance.
Day after day currently feels like a roller coaster ride, going up because of better than hoped for CPI numbers, down because of looming recession fears, and back up because of a less hawkish FED speech. Are we there yet? What do you think?